Prostat kanserinin inflamasyonla ilişkisi olabileceği düşünülmektedir. Prostat spesifik antijen prostat kanserinin tanı, tedavi ve takiplerde yaygın olarak kullanılmaktadır. C-reaktif protein inflamasyonda yaygın kullanılan bir belirteçtir. Çalışmamızda tPSA'sı >4,0 ng/ml olan ve biyopsi yapılmış hastalarda biyopsi sonucu benign prostat hiperplazisi (BPH) ve prostat kanseri (PCa) gelenler arasındaki serum CRP değerlerini karşılaştırdık. Gereç ve Yöntemler: tPSA >4,0 ng/dl olan ve biyopsiye karar verilen 182 hastada serum CRP ve sedimentasyon hızlarına bakıldı. Retrospektif değerlendirme yapıldı. 175 hastanın patolojik verilerine ulaşıldı. BPH ve PCa arasındaki CRP'ler Wilcoxon-Mann Whitney U ve Kruskal Wallis testleri yöntemleriyle çalışılarak karşılaştırıldı. İstatisiksel değerlendirmede p
It has been argued that prostate cancer may have an association with inflammation. Prostate specific antigen is widely used for diagnosis, treatment, and follow-up of prostate cancer. C-reactive protein is a widely utilized marker of inflammation. We compared serum CRP values between benign prostate hyperplasia (BPH) and pılmış hastalarda biyopsi sonucu benign prostat hiprostate cancer (PCa) diagnosed by prostate biopperplazisi (BPH) ve prostat kanseri (PCa) gelenler sy performed in patients with a tPSA level greater than 4.0 ng/dl. Material and Methods: Serum CRP and sedimentation rate were retrospectively assessed in 182 patients who had a tPSA level above 4.0 ng/dl and were scheduled to undergo prostate biopsy. Pathology results of 175 patients could be accessed. CRP levels of patients with BPH and PCa were testleri yöntemleriyle çalışılarak karşılaştırıldı. İscompared with each other using Wilcoxon-Mann tatisiksel değerlendirmede p<0.05 değeri anlamlılık Whitney U and Kruskal Wallis tests. A p value of less than 0.05 was considered statistically significant. Results: Both the analyses taking a CRP cutoff level of 0.5 mg/dl and quantitative serum CRP levels failed to show any significant difference between the BPH group (0.59+0.11 mg/dl) and the PCa group (0.55+0.18 mg/dl) (p=0.779; p=0.192). Sedimentation rate was also similar in the BPH ğerleri (18,98 mm/saat) ile PCa sedimentasyon hızı and PCa groups (18.98 mm/hour vs 18.18 mm/değerleri (18,18 mm/saat) birbirine benzerdi, aralahour; p=0.870).Conclusion: Our study could not demonstrate any significant difference between serum nın arasında serum CRP değerleri arasında anlamlı CRP levels of patients with BPH and PCa.fark bulunamadı
Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory meta- static prostate cancer. J Clin Oncol 2003; 21: 1232-7.
Ayyıldız SN, Ayyıldız A. Prostat kanseri tanısında PSA, PSA türevleri, ProPSA ve prostat sağlık indeksi. Turk J Urol 2014; 40: 82-8.
Liu Z-Q, Chu L, Fang J-M, et al. Prognostic role of C-re- active protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl 2014; 16: 467-471.
Graff JN, Beer TM. Editorial. The role of C-reactive protein in prostate cancer. Cancer 2013; 15: 3262.
Aletaha D, Smolen J. The simplified disease activity index (SDAI) and clinical disease activity index CDAI: a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 : 100-S108.
Young B, Gleeson M, Cripps AW. C-reactive protein: a criti- cal review. Pathology 1991; 23:118-124.
Mantovani A, Allavena P, Sica A, et al. Cancer-related in- flammation. Nature 2008; 454: 36-44.
Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med 1966; 123: 365-78.
Guo YZ, Pan L, Du CJ, et al. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev 2013; 14: 243-8.
Yu Q, Yu XF, Zhang SD, et al. Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. Asian Pac J Can- cer Prev 2013; 14: 5735-40.
Elsberger B, Lankston L, McMillan DC, et al. Presence of tu- moural C-reactive protein correlates with progressive pros- tate cancer. Prostate Cancer Prostatic Dis 2011; 14: 122-8.
Sox HC Jr, Liang MH. The erythrocyte sedimentation rate: guidelines for rational use. Ann Intern Med 1986; 104: 515- 523.
Mimeault M, Johansson SL, Batra SK. Pathobiological im- plications of the expression of EGFR, pAkt, NF-KB and MIC-1 in prostate cancer stem cells and their progenies. PloS ONE 2012; 7: 31919.
Ozden F, Saygin C, Uzunaslan D, et al. Expression of MMP- 1, MMP-9 and TIMP-2 in prostate carcinoma and their in- fluence on prognosis and survival. J Cancer Res Clin Oncol 2013; 139: 1373-82.
Mengus C, Le Magnen C, Trella E, et al. Elevated levels of circulating IL-7 and IL-15 in patients with early stage pros- tate cancer. J Transl Med 2011; 9: 162-168.
Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol 2013; 20: 161-71.
Allin KH, Nordesgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011; 48: 155-170.
Dai J, Tang K, Xiao W, et al. Prognostic significance of C-re- active protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2014; 15: 3369-3375.
Nakashima J, Kikuchi E, Miyajima A, et al. Simple strati- fication of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol Int 2008; 80: 129-33.
Lehrer S, Diamond EJ, Mamkine B, et al. C-reactive pro- tein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005; 95: 961-2.
Van Hemelrijck M, Jungner I, Walldius G, et al. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflamma- tion. Int J Cancer 2011; 129: 1485-92.
Markt SC, Rider JR, Penney KL, et al. Genetic variation across C-reactive protein and risk of prostate cancer. Pros- tate 2014; 74:1034-42.
Kutsal YG. Polypharmacy in elderly. Turkish J Geriatr 2006; 37-44.
Arslan S, Atalay A, Kutsal YG. Drug use in older people. J Am Geratr Soc 2002; 50: 1163-1168.
Esengen S, Seckin U, Borman P, et al. Drug consumption in a group of elderly residents of a nursing home: relationship to cognitive impairment and disability. J Am Med Dir Assoc 2000; 1: 197-201.
Wu JY, Leung WY, Chang S, et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in pa- tients receiving polypharmacy: randomised controlled trial. BMJ 2006; 333: 522-529.
Steinman MA, Seth Landefeld C, Rosenthal GE, et al. Poly- pharmacy and prescribing quality in older people. J Am Geriatr Soc 2006; 54: 1516-23.
Cannon KT, Choi MM, Zuniga MA. Potentially inappropri- ate medication use in elderly patients receiving home health care: a retrospective data analysis. An J Geriatr Pharmaco- ther 2006; 4: 134-43.
Kim Y, Jeon Y, Lee H, et al. The prostate cancer patient had higher C-reactive protein than BPH patient. Korean J Urol 2013; 54: 85-88.
Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of cele- coxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64: 3334-43.
Kramer G, Mitteregger D, Maj-Hes A, et al. Chronic inflam- mation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer. Urologe A 2007; 46: 1095-6.
MacLennon GT, Eisenberg R, Fleshman RL, et al. The influ- ence of chronic inflammation in prostatic carcinogenesis: A 5-year follow up study. J Urol 2006; 176: 1012-6.
Jacobs EJ, Newton CC, Stevens VL, et al. A large cohort study of long-term acetaminophen use and prostate cancer incidence. Cancer Epidemiol Biomarkers Prev 2011; 20: 1322-1328.
Fowke JH, Motley SS, Smith JA, et al. Association of nonste- roidal antiinflammatory drugs, prostate specific antigen and prostate volume. J Urol 2009; 181: 2064-70.
McCall P, Catlow J, McArdle PA, et al. Tumoral C-reactive protein and nuclear factor kappa-B expression are associ- ated with clinical outcome in patients with prostate cancer. Cancer Biomark 2011-2012; 10: 91-9.
Lucia MS, Torkko KC. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory ratio- nale. J Urol 2004; 171: 30-4.